An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Launched by HOFFMANN-LA ROCHE · Sep 23, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients at least 18 years of age
• • Patients with a diagnosis of active moderate to severe rheumatoid arthritis (RA)
• • Oral corticosteroids and nonsteroidal anti-inflammatory are permitted if on a stable dose regimen for \>/= 4 weeks prior baseline
• • Permitted non-biologic disease-modifying anti-rheumatic drugs (DMARDs) used alone or in combination are allowed if at a stable dose for at least 4 weeks prior to baseline
• • Receiving treatment on an outpatient basis, not including tocilizumab
• • Females of childbearing potential and males with female partners of childbearing potential may participate in this study only if using a reliable means of contraception for at least 5 months following the last dose tocilizumab
• • Previous or current treatment with methotrexate with an inadequate response to methotrexate, intolerance to methotrexate or treatment with methotrexate was considered as inappropriate
• • Evidence of one or more erosions in hands or feet assessed by X-ray attributable to RA or magnetic resonance imaging (MRI) of wrist of metacarpophalangeal (MCP) joints of dominant hand
• Exclusion Criteria:
• • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
• • Rheumatic autoimmune disease other than rheumatoid arthritis
• • Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis
• • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
• • Prior history of current inflammatory joint disease other than RA
• • Exposure to tocilizumab at any time prior to baseline
• • Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of screening
• • Previous treatment with any cell-depleting therapies
• • Treatment with intravenous (IV) gamma globulin, plasmapheresis within 6 months of baseline
• • Intraarticular (IA) or parenteral corticosteroids within 4 weeks prior to baseline
• • Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation
• • Treatment with 2 or more anti-tumor necrosis factor (TNF) agents or any other biologic agent at any time prior to screening
• • Evidence of serious uncontrolled concomitant disease (e.g., cardiovascular, nervous system, pulmonary)
• • History of diverticulitis, diverticulosis requiring antibiotic treatment, or chromic ulcerative lower gastrointestinal (GI) disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower genitourinary (GU) conditions that might predispose to perforation
• • Known active current or history of recurrent infections